Chronic Myeloproliferative Disorders Completed Phase 1 Trials for Ruxolitinib (DB08877)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01164163INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseTreatment